CAR T-cell Therapy Market

Chimeric antigen receptor (CAR) T-cell therapy is evolving as a revolutionary treatment for the various types of cancers, especially for hematological malignancies. It involves genetically engineered T cells (either a patient’s own or a healthy donor) to express a synthetic receptor know as chimeric antigen receptor (CAR), after re-transfused into the patient body these CAR T-cells targets and attach to a specific antigen on the tumor surface to kill the cancerous cells.

By Q3 2020, there are a total of 03 approved CAR T-cell therapy products, including KYMRIAH®, YESCARTA®, and the most recently approved TECARTUS™ (formerly KTE-X19). Furthermore, two CAR T-cell therapies BB2121, and JCAR017 are expected to get market approval by the end of 2020 or in early 2021.

The successful launch of CAR T-cell therapy products has lured substantial investment into the industry and attracted a growing number of market competitors, ranging from spin-offs to large conglomerates.

Pharmaceutical companies are showing an appetite for CAR T-cell therapy technologies, engaging in licensing agreements, R&D collaborations, and M&A deal-making aimed to bring new CAR T-cell therapies to market.

There are currently more than 300 companies operating in the cell therapy domain and most of them lie in china and the USA. We cover the 51 key market players from the four main geographical regions including North America, Europe, APAC, and LAMEA.